Stevens Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stevens Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,522	Closed	-$245K	–	214
2025 Q3	$245K	Buy	+4,522	New	+$259K	0.03%	223
2019 Q4	–	Sell	-18,738	Closed	-$1.26M	–	608
2019 Q3	$1.26M	Sell	18,738 -968	-5%	-$74.6K	0.11%	195
2019 Q2	$1.69M	Sell	19,706 -17,240	-47%	-$1.47M	0.08%	279
2019 Q1	$3.28M	Buy	+36,946	New	+$3.42M	0.14%	194
2017 Q4	–	Sell	-20,048	Closed	-$1.87M	–	826
2017 Q3	$1.87M	Sell	20,048 -4,118	-17%	-$364K	0.07%	325
2017 Q2	$2.19M	Buy	24,166 +19,116	+379%	+$1.74M	0.08%	295
2017 Q1	$443K	Buy	+5,050	New	+$449K	0.02%	608
2016 Q4	–	Sell	-5,040	Closed	-$466K	–	880
2016 Q3	$466K	Sell	5,040 -1,032	-17%	-$97.2K	0.02%	588
2016 Q2	$472K	Buy	+6,072	New	+$516K	0.02%	594
2015 Q4	–	Sell	-32,382	Closed	-$3.41M	–	933
2015 Q3	$3.41M	Buy	+32,382	New	+$4.33M	0.16%	158
2014 Q3	–	Sell	-9,405	Closed	-$585K	–	1006
2014 Q2	$585K	Buy	+9,405	New	+$568K	0.02%	623
2014 Q1	–	Sell	-31,715	Closed	-$2.23M	–	1071
2013 Q4	$2.23M	Sell	31,715 -13,260	-29%	-$901K	0.07%	320
2013 Q3	$3.25M	Sell	44,975 -13,462	-23%	-$895K	0.1%	262
2013 Q2	$3.26M	Buy	+58,437	New	+$3.64M	0.11%	230

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stevens Capital Management's BMRN Position: Q4 2025 in Review

Stevens Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,522 shares — an estimated $245K sold.

Stevens Capital Management first reported a position in BMRN in Q2 2013 and held it in 14 quarters. The position peaked at $3.41M in Q3 2015. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Stevens Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Stevens Capital Management sold 4,522 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $245K.
Stevens Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Stevens Capital Management's BioMarin Pharmaceuticals position peaked at $3.41M in Q3 2015.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Stevens Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.